KCT0005190
Active, not recruiting
未知
Effectiveness of theraPeutic drug mOnitoring (TDM) on mucosal and transmural healing in pediatric patients with moderate to severe luminal CroHn’s disease newly receiving Remsima(infliximab): EPOCH study
ConditionsDiseases of the digestive system
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the digestive system
- Sponsor
- Samsung Medical Center
- Enrollment
- 116
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Pediatric patients aged 6–20 years with moderate to severe CD who requires infliximab.
- •\[Patients with Pediatric Crohn’s Disease Activity Index (PCDAI) \=30 in the European Crohn’s and Colitis Organisation and European Society of Pediatric Gastroenterology, Hepatology, and Nutrition guidelines.]
- •2\) Pediatric patients without biologic agent administration in previous treatments.
- •3\) Pediatric patients who do not show treatment response or tolerance to corticosteroids, immunomodulators, and primary nutritional therapy, or those for whom these treatments are contraindicated.
- •4\) Pediatric patients whose legal guardians and who themselves provided consent to participation in this study.
Exclusion Criteria
- •1\) Patients with mild CD
- •2\) Patients aged less than 6 years, or 21 years or older
- •3\) Patients with ulcerative colitis
- •4\) Patients with a history of hypersensitivity to humanized protein
- •5\) Patients who require infliximab treatment for anal fissure
- •6\) Patients who are taking corticosteroids (Patients may be included if the steroid dosage is being tapered to halt steroid use.)
- •7\) Patients with a previous history of tuberculosis
- •8\) Patients who have had tuberculosis but have been confirmed to have undergone anti\-tuberculosis therapy for the minimum period required by a tuberculosis therapy guideline, and are willing to complete the therapy may be included.
- •9\) Patients who visit a doctor for a medical check\-up, and have purified protein derivative (PPD) skin test or interferon\-? release assay (IGRA) results within the last 6 months may be included.
- •10\) Patients with chronic type B hepatitis not receiving any treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Influence of therapeutic drug monitoring (TDM) on the tolerability and efficacy of 5-FU-containing chemotherapy in patients with colorectal carcinoma in the colorectal center at St.-Franziskus-Hospital Münster: a prospective, monocentric observational study.C18Malignant neoplasm of colonDRKS00026926St. Franziskus-Hospital GmbH50
Recruiting
Not Applicable
TDM in MMTOpiod dependenceMental Health - AddictionACTRN12606000033549The Langton Centre90
Withdrawn
Not Applicable
se of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19COVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620000447954Royal Brisbane & Women's Hospital150
Recruiting
Phase 3
Assessment of Memantine Drug Levels in Blood Among Indian Patients with Brain Metastases Treated with Radiation TherapyHealth Condition 1: C719- Malignant neoplasm of brain, unspecifiedCTRI/2024/04/066217Amrita School of Pharmacy
Recruiting
Not Applicable
on-interventional study on Therapeutic Drug Monitoring (TDM) in patients with renal cell carcinoma and on the feasibility of using Volumetric Absorptive Microsampling (VAMS) for sample collection (ON-TARGET)C64Malignant neoplasm of kidney, except renal pelvisDRKS00025325Central European Society for Anticancer Drug Research (CESAR) e.V.80